mineral oil (OTC)

Brand and Other Names:Kondremul Plain
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

liquid

  • 100%

Constipation

15-45 mL/day PO, single or divided doses

Kondremul: 30-75 mL/day

Dosage Forms & Strengths

liquid

  • 100%

Constipation

<6 years

  • 15-30 mL/year of age; not to exceed 240 mL/day

6-12 years

  • 5-15 mL/day divided qDay, single or divided doses
  • Kondremul: 10-25 mL/day

>12 years

  • 15-45 mL/day PO, single or divided doses
  • Kondremul: 30-75 mL/day

Next:

Interactions

Interaction Checker

and mineral oil

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (4)

                • beta carotene

                  mineral oil decreases levels of beta carotene by drug binding in GI tract. Use Caution/Monitor.

                • digoxin

                  mineral oil decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                • levonorgestrel oral/ethinylestradiol/ferrous bisglycinate

                  mineral oil decreases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely.

                • vitamin D

                  mineral oil will decrease the level or effect of vitamin D by Other (see comment). Use Caution/Monitor. Avoid concomitant use of mineral oil and vitamin D supplements to avoid risk of decreased absorption of vitamin D. Applies to only oral administration of these agents.

                Minor (22)

                • antithrombin alfa

                  mineral oil decreases levels of antithrombin alfa by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • antithrombin III

                  mineral oil decreases levels of antithrombin III by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • argatroban

                  mineral oil decreases levels of argatroban by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • bemiparin

                  mineral oil decreases levels of bemiparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • bivalirudin

                  mineral oil decreases levels of bivalirudin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • dabigatran

                  mineral oil decreases levels of dabigatran by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • dalteparin

                  mineral oil decreases levels of dalteparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • docusate

                  docusate increases levels of mineral oil by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • enoxaparin

                  mineral oil decreases levels of enoxaparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • ethinylestradiol

                  mineral oil decreases levels of ethinylestradiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • fondaparinux

                  mineral oil decreases levels of fondaparinux by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • heparin

                  mineral oil decreases levels of heparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • mestranol

                  mineral oil decreases levels of mestranol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • phenindione

                  mineral oil decreases levels of phenindione by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • protamine

                  mineral oil decreases levels of protamine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • sulfadiazine

                  mineral oil decreases levels of sulfadiazine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • sulfamethoxazole

                  mineral oil decreases levels of sulfamethoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • sulfisoxazole

                  mineral oil decreases levels of sulfisoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • vitamin A

                  mineral oil decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • vitamin E

                  mineral oil decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • vitamin K1 (phytonadione)

                  mineral oil decreases levels of vitamin K1 (phytonadione) by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • warfarin

                  mineral oil decreases levels of warfarin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Lipid pneumonitis if reclined

                Incontinence of feces

                Intestinal malabsorption

                Impaired absorption of fat-soluble vitamins

                Rectal discharge

                Anal pruritus and irritation

                Abdominal cramps

                Nausea

                Vomiting

                Lipid pneumonitis with aspiration

                Previous
                Next:

                Warnings

                Contraindications

                Abdominal pain, nausea, vomiting, or other symptoms of appendicitis or acute surgical abdomen

                Fecal impaction, intestinal obstruction or perforation, colostomy, ileostomy, ulcerative colitis, diverticulitis

                Bedridden, geriatric, debilitated, or pregnant pts

                Patients with esophageal or gastric retention, dysphagia, or hiatal hernia

                Cautions

                Conditions that interfere with swallowing or epiglottal function may increase risk of aspiration, which can result in lipid pneumonitis

                Do not administer >1 week

                Aspiration risk increases in the elderly

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: Not recommended (no FDA risk factor assigned)

                Lactation: Not known if excreted in breast milk; not recommended

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Emollient; retards colonic absorption of water; decreases water absorption and lubricates intestine, which eases passage of stool

                Pharmacokinetics

                Onset of action: 6-8 hr (PO)

                Distribution: Colon

                Excretion: Feces

                Absorption: minimal

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.